In vitro effects of bethanechol on specimens of intestinal smooth muscle obtained from the duodenum and jejunum of healthy dairy cows

Julia B. R. Pfeiffer Clinic for Ruminants, Vetsuisse Faculty, University of Berne, 3012 Berne, Switzerland

Search for other papers by Julia B. R. Pfeiffer in
Current site
Google Scholar
PubMed
Close
 Dr med vet
,
Meike Mevissen Division of Veterinary Pharmacology and Toxicology, Vetsuisse Faculty, University of Berne, 3012 Berne, Switzerland

Search for other papers by Meike Mevissen in
Current site
Google Scholar
PubMed
Close
 Dr med vet, Dr habil
,
Adrian Steiner Clinic for Ruminants, Vetsuisse Faculty, University of Berne, 3012 Berne, Switzerland

Search for other papers by Adrian Steiner in
Current site
Google Scholar
PubMed
Close
 Dr med vet, MS, Dr habil
,
Christopher J. Portier Laboratory of Molecular Toxicology, Environmental Systems Biology and Risk Assessment, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709

Search for other papers by Christopher J. Portier in
Current site
Google Scholar
PubMed
Close
 PhD
, and
Mireille Meylan Clinic for Ruminants, Vetsuisse Faculty, University of Berne, 3012 Berne, Switzerland

Search for other papers by Mireille Meylan in
Current site
Google Scholar
PubMed
Close
 Dr med vet, PhD, Dr habil

Abstract

Objective—To describe the in vitro effects of bethanechol on contractility of smooth muscle preparations from the small intestines of healthy cows and define the muscarinic receptor subtypes involved in mediating contraction.

Sample Population—Tissue samples from the duodenum and jejunum collected immediately after slaughter of 40 healthy cows.

Procedures—Cumulative concentration-response curves were determined for the muscarinic receptor agonist bethanechol with or without prior incubation with subtype-specific receptor antagonists in an organ bath. Effects of bethanechol and antagonists and the influence of intestinal location on basal tone, maximal amplitude (Amax), and area under the curve (AUC) were evaluated.

Results—Bethanechol induced a significant, concentration-dependent increase in all preparations and variables. The effect of bethanechol was more pronounced in jejunal than in duodenal samples and in circular than in longitudinal preparations. Significant inhibition of the effects of bethanechol was observed after prior incubation with muscarinic receptor subtype M3 antagonists (more commonly for basal tone than for Amax and AUC). The M2 receptor antagonists partly inhibited the response to bethanechol, especially for basal tone. The M3 receptor antagonists were generally more potent than the M2 receptor antagonists. In a protection experiment, an M3 receptor antagonist was less potent than when used in combination with an M2 receptor antagonist. Receptor antagonists for M1 and M4 did not affect contractility variables.

Conclusions and Clinical Relevance—Bethanechol acting on muscarinic receptor sub-types M2 and M3 may be of clinical use as a prokinetic drug for motility disorders of the duodenum and jejunum in dairy cows.

Abstract

Objective—To describe the in vitro effects of bethanechol on contractility of smooth muscle preparations from the small intestines of healthy cows and define the muscarinic receptor subtypes involved in mediating contraction.

Sample Population—Tissue samples from the duodenum and jejunum collected immediately after slaughter of 40 healthy cows.

Procedures—Cumulative concentration-response curves were determined for the muscarinic receptor agonist bethanechol with or without prior incubation with subtype-specific receptor antagonists in an organ bath. Effects of bethanechol and antagonists and the influence of intestinal location on basal tone, maximal amplitude (Amax), and area under the curve (AUC) were evaluated.

Results—Bethanechol induced a significant, concentration-dependent increase in all preparations and variables. The effect of bethanechol was more pronounced in jejunal than in duodenal samples and in circular than in longitudinal preparations. Significant inhibition of the effects of bethanechol was observed after prior incubation with muscarinic receptor subtype M3 antagonists (more commonly for basal tone than for Amax and AUC). The M2 receptor antagonists partly inhibited the response to bethanechol, especially for basal tone. The M3 receptor antagonists were generally more potent than the M2 receptor antagonists. In a protection experiment, an M3 receptor antagonist was less potent than when used in combination with an M2 receptor antagonist. Receptor antagonists for M1 and M4 did not affect contractility variables.

Conclusions and Clinical Relevance—Bethanechol acting on muscarinic receptor sub-types M2 and M3 may be of clinical use as a prokinetic drug for motility disorders of the duodenum and jejunum in dairy cows.

All Time Past Year Past 30 Days
Abstract Views 61 0 0
Full Text Views 7056 6858 6099
PDF Downloads 174 112 14
Advertisement